Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05363449 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis
A Phase 1 study of Tinea Pedis and Tinea Cruris, sponsored by Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
- 5
- Study locations
NCT05363449 is a Phase 1 study of Tinea Pedis and Tinea Cruris that has completed, run by Therapeutics. The registered enrollment target is 42 participants, below the 322-participant average among 9 other Tinea Pedis trials with a reported enrollment target (87% lower). The trial reports 5 study locations across 2 states.
The verdict
NCT05363449, a Phase 1 study of Tinea Pedis and Tinea Cruris, has completed, sponsored by Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
- 5
- Study locations
Study Summary
This Phase 1 study has been designed to determine the safety, tolerability and pharmacokinetics (PK) of UHE 103 Cream compared to Naftin Cream, 2% under maximal use conditions for 2 weeks treatment in subjects with tinea cruris and/or tinea pedis
Conditions Studied
Interventions
- DRUG UHE-103 Cream
- DRUG Naftin (naftifine hydrochloride) Cream
Study Locations (5)
Texas
- Site #2 - Austin
- Site #3 - College Station
- Site #4 - Houston
California
- Site #1 - San Diego
- Site #5 - Thousand Oaks
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2022-02-17 |
| Est. Completion | 2023-11-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05363449
The ClinicalTrials.gov registry entry for NCT05363449 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 322-participant average among 9 other Tinea Pedis trials with a reported enrollment target (87% lower). The listed sponsor is Therapeutics, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Tinea Pedis appearing as the primary indexed condition, and to 2 interventions - of which UHE-103 Cream is the first listed.
NCT05363449 reports 5 study locations spanning 2 distinct geographic areas - top geographies include Texas, California.
Frequently Asked Questions
What is clinical trial NCT05363449 about?
NCT05363449 is a clinical study titled "Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis". This Phase 1 study has been designed to determine the safety, tolerability and pharmacokinetics (PK) of UHE 103 Cream compared to Naftin Cream, 2% under maximal use conditions for 2 weeks treatment in subjects with tinea cruris and/or tinea pedis
What is the current status of trial NCT05363449?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2022-02-17. Estimated completion is 2023-11-14.
What conditions does trial NCT05363449 study?
This clinical trial studies the following conditions: Tinea Pedis, Tinea Cruris.
What interventions are being tested in trial NCT05363449?
The interventions under investigation include: UHE-103 Cream (DRUG), Naftin (naftifine hydrochloride) Cream (DRUG).
Who is sponsoring clinical trial NCT05363449?
This trial is sponsored by Therapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05363449 being conducted?
This trial has 5 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tinea Pedis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Topical Tolnaftate Stick for Tinea Pedis: An Open-Label Interventional Study
RECRUITING · Phase 2
-
A Study of Econazole Foam 1% in Athlete's Foot
COMPLETED · Phase 2
-
Spread of Dermatophytes Among Families
COMPLETED
-
BE Study of Naftifine HCL
COMPLETED · Phase 3
-
A Study Comparing the Efficacy of TA103 and the Placebo Control in the Treatment of Interdigital Tinea Pedis.
COMPLETED · Early Phase 1
-
Three-Arm Trial of Novel Treatment for Tinea Pedis
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.